One study showed that TAMs are more prone to glycolytic metabolism in the hepatocellular carcinoma (HCC) tumor microenvironment, which depends on the activation of WNT2b/β-catenin/MYC signaling [52]. The gene discussed is MYC; the disease is hepatocellular carcinoma.